Unknown Analyst

[Audio Gap] Bank of America. Today, I'm joined by Anshul Maheshwari, as Chief Financial Officer and Chief Operating Officer for SI-BONE. Thanks for joining us, Anshul.

Anshul Maheshwari
COO & CFO

Yes. Thanks for having us.

Unknown Analyst

So just to start out maybe more big picture on the story. You're seeing a lot of current momentum in the business, set up with a nice multiyear tailwinds in reimbursement, surgeon adoption and new products. So what excites you most about the SI-BONE story today? And what do you think maybe is most underappreciated by investors?

Anshul Maheshwari
COO & CFO

Yes. Thanks for the question. We actually announced our earnings last night. And if I was to break down things that we as a company are really excited about, I'd break it down into 4 buckets. The first one would be innovation. The second would be engagement. The third would be commercial expansion, the fourth would be growth and profitability. And we're firing all cylinders on all those 4 priorities.

So starting with innovation, we just launched another product in the SI joint space in Q1, INTRA Ti. That's focused on ASCs and interventional specifically. That product is tracking really well. We've got another product that we expect to commercialize in the fourth quarter. That is our third breakthrough device product. That's going after one of the largest unmet needs in spine surgery and it's going to be a massive expansion of our TAM, a huge opportunity for us going after the same [indiscernible] and actually have a lot of procedure and physician density. So really excited about the innovation side for this year.